DAY TWO
8:30 am Morning Refreshments
9:20 am Chair’s Opening Remarks
Translating Novel Obesity Therapies into Practice Using Clinical Insights to Improve Patient Personalisation for More Effective Treatment
9:30 am Building Precision Medicine-Based Approaches to Address End Organ Fibroinflammation in Metabolically Challenged Individuals
Synopsis
- Building precision medicine approaches to address end-organ damage in metabolically challenged patients provides the advantage of targeting the root cause of the disease, which leads to personalized, more effective therapies
- Focusing on fibroinflammation offers the advantage of addressing the specific pathological process driving organ failure, which results in improved clinical outcomes and better long-term quality of life
- Developing a multi-faceted therapeutic strategy provides the advantage of leveraging multiple points of intervention to restore metabolic homeostasis, which leads to more durable treatment effects for complex chronic diseases
10:00 am From “Treat to Target” to Tailored Treatment: Leveraging Clinical Insights with Eli Lilly’s Novel Therapies to Personalize Obesity Care
Synopsis
- Implementing a “Treat to Target” strategy allows clinicians to use data-driven insights for personalization, which results in more effective and proactive patient care
- Leveraging next-generation therapies from Eli Lilly provides new opportunities to reach specific treatment goals for individual patients, ultimately leading to clinically meaningful and sustained health improvements
- This paradigm shift in obesity management fosters a continuous feedback loop, which optimizes therapeutic outcomes, resulting in better patient adherence and long-term success
10:30 am Morning Break & Networking
Refining Dosing Regimens to Support Patient Commitment & Amplify Therapeutic Impact in Real-World Settings
11:00 am Roundtable Discussion: Implementing Flexible Dosing Schedules for Accommodating Patient Lifestyles to Improve Treatment Consistency for Better Long-Term Results
Synopsis
- Offering once-weekly or monthly dosing options for reduced administration burden to enhance patient convenience for improved compliance
- Developing personalized dosing algorithms for individual metabolic profiles to optimize therapeutic response for maximized weight loss efficacy
- Providing patient support programs for education and adherence coaching to address barriers to compliance for sustained treatment engagement
12:00 pm Preclinical Development of Oral Small Molecule GLP-1 Agonists: Challenges & Solutions
Synopsis
- Screening paradigms for in vitro cell efficacy, ADME and DMPK
- Validating appropriate in vivo pharmacodynamic models
- In vivo efficacy and safety assessments: early and often
- Clinical Candidate nomination: data from Ambrosia’s proprietary program to be presented
12:30 pm Lunch
Developing Tolerability-Driven Therapies to Increase Patient Comfort & Sustain Treatment Engagement/center>
1:30 pm Next-Generation Obesity Therapeutics: Long-Acting Antibodies for Improved Quality of Weight Loss
Synopsis
- Evaluating how the long-acting nature of next-generation antibodies improves patient adherence and convenience, providing a clear advantage in sustaining long-term weight loss and ensuring superior patient outcomes
- Discussing how these antibodies are being engineered for improved tolerability and reduced side effects, offering a clear benefit in enhancing patient comfort and ensuring more durable treatment engagement
- Analyzing how these long-acting therapies are being designed to not only reduce body weight but also improve body composition, providing a distinct advantage in promoting a higher quality of weight loss with a focus on muscle preservation and metabolic health
2:00 pm Designing a Next-Generation Therapeutic with Unmatched Tolerability to Drive Long-Term Patient Continuation
Synopsis
- Mitigating common side effects through targeted drug design and optimized delivery methods to reduce GI distress and improve the overall patient experience
- Utilizing advanced formulation science to ensure consistent drug exposure and minimize dose-related adverse events for a safer, more predictable therapeutic profile
- Integrating behavioral insights into the development process to create a treatment that aligns with patient lifestyles and maximizes adherence beyond a clinical setting
2:30 pm Panel Discussion: Synthesizing Breakthrough Discoveries to Chart Future Directions for Accelerating Therapeutic Innovation for Broader Patient Impact
Synopsis
- Integrating cross-disciplinary insights for comprehensive understanding to identify synergistic opportunities for more effective drug development strategies
- Forecasting emerging trends and technologies for proactive research planning to anticipate future challenges for sustainable therapeutic pipelines
- Fostering global collaborations and partnerships for shared knowledge and resources to expedite clinical translation for faster patient access to novel treatments